Drugs / ATIR101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00993486 | Jan 2005 → Oct 2008 | hematopoietic and lymphoid system neoplasm | Kiadis Pharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02500550 | Oct 2015 → Jul 2018 | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Kiadis Pharma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02999854 | Nov 2017 → Nov 2021 | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Kiadis Pharma | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATIR101 | “A photodepletion strategy to eliminate alloreactive T cells from mismatched donor lymphocyte infusions (enabling administration without immunosuppression), was used to develop...” PMID 31135970 ↗ May 2019 |
| Modality | Cell therapy | “Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation” PMID 31135970 ↗ May 2019 |
| Route | Intravenous | “Single intravenous infusion” NCT00993486 ↗ |